Nivolumab as first-line treatment in non-small cell lung cancer patients-key factors: tumor mutation burden and PD-L1 ≥50.

Transl Lung Cancer Res

Department of Respiratory and Critical Care Medicine, Changhai Hospital, Second Military Medical University, Shanghai 200000, China.

Published: February 2018

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835639	PMC
http://dx.doi.org/10.21037/tlcr.2018.01.04	DOI Listing

Publication Analysis

nivolumab first-line

first-line treatment

treatment non-small

non-small cell

cell lung

lung cancer

cancer patients-key

patients-key factors

factors tumor

tumor mutation

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!